{"id":"stander-treatment-pregabalin","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Dizziness"},{"rate":"15-25","effect":"Somnolence"},{"rate":"5-15","effect":"Dry mouth"},{"rate":"5-10","effect":"Edema (peripheral)"},{"rate":"5-10","effect":"Weight gain"},{"rate":"5-10","effect":"Blurred vision"},{"rate":"5-10","effect":"Ataxia"}]},"_chembl":{"chemblId":"CHEMBL1059","moleculeType":"Small molecule","molecularWeight":"159.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to presynaptic calcium channels, pregabalin decreases calcium influx and subsequently reduces the release of glutamate, noradrenaline, and substance P. This leads to reduced neuronal excitability and pain signal transmission. The drug is effective in conditions characterized by neuropathic pain and hyperexcitability of the nervous system.","oneSentence":"Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:34.945Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury)"},{"name":"Partial-onset seizures (adjunctive therapy)"},{"name":"Generalized anxiety disorder"},{"name":"Fibromyalgia"}]},"trialDetails":[{"nctId":"NCT07313111","phase":"PHASE4","title":"Thymoquinone as an add-on Therapy for the Management of Patients With Diabetic Peripheral Neuropathy","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2024-07-01","conditions":"Diabetic Peripheral Neuropathy (DPN)","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"stander treatment pregabalin","genericName":"stander treatment pregabalin","companyName":"Hawler Medical University","companyId":"hawler-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury), Partial-onset seizures (adjunctive therapy), Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}